Wednesday, July 8, 2026

Patent intelligence · US

US 6225292

Inhibitors of DNA immunostimulatory sequence activity

expired A61KA61K2039/55561A61K2039/57A61K38/00
Status expired
Linked drugs 3
Pipeline programs 6
Years to expiry 0
Applicant portfolio 8,292
Patent details — US 6225292
Jurisdiction
US
Status
expired
Grant date
May 1, 2001
Expiration
Apr 26, 2021
Claims
82
CPC classes
A61K, A61K2039/55561, A61K2039/57, A61K38/00
View on Google Patents ↗

Quick answer

US 6225292 (Inhibitors of DNA immunostimulatory sequence activity) is held by The Regents of the University of California. Status: expired. Granted May 1, 2001. Expires Apr 26, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
82
CPC classes
A61K, A61K2039/55561, A61K2039/57, A61K38/00, A61K39/39, A61P

More from The Regents of the University of California

Related pharmaceutical patents in our USPTO index.

  1. US 12428463

    Chimeric antigen receptors targeting abnormal glycobiology

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Expires Sep 25, 2045

    granted
  2. US 12427148

    Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  3. US 12428416

    ERK inhibitors and uses thereof

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  4. US 12427151

    Compositions and method of treating cancer

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  5. US 12427197

    Methods of producing cobalt nanoparticles and hollow metal nanospheres

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  6. US 12428489

    Human PD-L2 antibodies and methods of use therefor

    The Board of Regents of the University of Texas System · Expires Sep 25, 2045

    granted
  7. US 12427155

    Treatment for tau-related diseases

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  8. US 12428455

    Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells

    The Regents of the University of California · Expires Sep 25, 2045

    granted

Frequently asked questions

What is US patent 6225292?

US 6225292 (Inhibitors of DNA immunostimulatory sequence activity) is held by The Regents of the University of California. Status: expired. Granted May 1, 2001. Expires Apr 26, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 6225292?

The Regents of the University of California is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.

When does US 6225292 expire?

Our index shows an expiration date of Apr 26, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.